Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ES104 in advanced or metastatic colorectal cancer
NCT05167448Phase 2Terminated
- Sponsor
- Elpiscience
- Start
- Feb 2022
- Primary completion
- Mar 2023
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tovecimig in colorectal cancer (CRC), sponsored by Elpiscience. Started Feb 2022; status: terminated.
02
Drugs
tovecimig
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05167448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05167448.